Researchers study cancer in dogs to ultimately help humans with same disease

June 17, 2016, The Ohio State University
In an effort to expedite medical advances for osteosarcoma and other rare cancers that occur in both humans and dogs, The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Institute and College of Veterinary Medicine through the Comparative Oncology Signature Research Program. Credit: The Ohio State University Comprehensive Cancer Center

A new collaborative research program pairs oncologists who treat childhood and adult sarcomas with veterinarians who manage the same cancers in canine patients.

The ultimate goal, says director Cheryl London, DVM, PhD, is to speed up the pace of translational research discoveries and new treatments for sarcoma, a diverse group of cancerous tumors that occur in soft tissue or bone.

Established in 2016 by The Ohio State University College of Veterinary Medicine, the Comparative Oncology Signature Research Program is a partnership between the vet school and The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) that integrates nearly 40 scientific investigators from Ohio State's colleges of medicine, pharmacy, nursing and veterinary medicine along with researchers from Nationwide Children's Hospital.

Connecting Canine and Human Cancers

The Comparative Oncology Signature Research Program addresses a significant challenge in the current clinical trials model: the lack of a close comparative testing model for translating drug discoveries to application in cancer.

"It can take up to 10 years to fully develop and test drugs for human application - and 50 to 90 percent of the oncology drugs that make it to human testing fail because the most common testing model (a mouse) is very different than a human," says London. "Dogs are a natural analog to human sarcoma because the diseases are so similar across the two species. This represents exceptional potential to accelerate the drug discovery process for the benefit of both our canine patients and human patients."

Ohio State vet Elizabeth Schuh, DVM, checks Marley, a young dog recently treated for a bone cancer known as osteosarcoma. Dogs get osteosarcoma with a higher frequency that people but the disease nearly identical in humans and canines. Credit: The Ohio State University Comprehensive Cancer Center

An estimated 15,000 individuals are diagnosed with sarcoma annually, with roughly 3,000 of those cancers occurring in the bone. About 800 of those cases are osteosarcoma, a rare form of bone sarcoma that typically occurs in youth under age 18. Dogs experience a high rate of sarcoma, particularly osteosarcoma with over 10,000 cases reported per year.

"We haven't had a new drug in osteosarcoma in over 30 years because the disease is rare. The cost of researching, developing and bringing a drug to market in the United States is too prohibitive for pharmaceutical companies to make that type of investment for a rare disease," says Joel Mayerson, MD, an oncologic orthopaedic surgeon who specializes in sarcoma at The OSUCCC - James. "Unfortunately, while surgery can be curative for many patients it isn't for everyone. Without new drug therapies effective at controlling the cancer, survival rates have remained stagnant."

Clinical trials are actively underway through the Comparative Oncology Signature Research Program, including two canine looking at novel therapies to treat the spread of osteosarcoma. If the therapies prove effective in dogs, they will move on to human testing.

In addition to providing clinical trial research support for new treatment approaches, the Comparative Oncology Signature Research Program is focused on research to identify the key genetic and molecular abnormalities of ; developing advanced imaging tools for improved diagnosis and pre-surgery imaging accuracy; and modern surgical techniques for achieving optimal cancer control and preserving anatomical function.

Explore further: A common enemy: Through clinical trials, veterinarian fights cancer in animals, humans

Related Stories

A common enemy: Through clinical trials, veterinarian fights cancer in animals, humans

June 13, 2016
Raelene Wouda's passion for improving cancer treatment starts with our four-legged friends.

Immunotherapy effective against some types of sarcoma

June 6, 2016
An existing cancer immunotherapy drug reduces tumor size in some types of rare connective tissue cancers, called sarcomas, report researchers at the University of Pittsburgh Cancer Institute (UPCI). Additional analyses of ...

Dogs accelerate the advance of new cancer treatments for both pets and people

February 4, 2016
A Science Translational Medicine review suggests integrating dogs with naturally occurring cancers into studies of new drug therapeutics could result in better treatments for our four-legged friends while helping inform therapeutic ...

Gene signatures predict doxorubicin response in K9 osteosarcoma

April 20, 2015
There are two chemotherapies commonly used to treat bone cancer in dogs: doxorubicin and carboplatin. Some dogs respond better to one drug than to the other. But until now, the choice has been left largely to chance. New ...

Can dogs help us develop better cancer treatments?

December 14, 2015
Will Eward, DVM, MD, works to find better treatments for a cancer called sarcoma. It makes no difference to him that half of his patients walk on four legs and bark at the doorbell.

CTCA at Western launches immunotherapy clinical trial aimed at soft-tissue cancers

September 18, 2015
Cancer Treatment Centers of America (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona, has begun Phase II of another arm of its multi-arm clinical trial that combines immunotherapy with chemotherapy.

Recommended for you

Magnetized wire could be used to detect cancer in people, scientists report

July 16, 2018
A magnetic wire used to snag scarce and hard-to-capture tumor cells could prove to be a swift and effective tactic for early cancer detection, according to a study by researchers at the Stanford University School of Medicine.

Researchers suggest new treatment for rare inherited cancers

July 16, 2018
Studying two rare inherited cancer syndromes, Yale Cancer Center (YCC) scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery, published today in Nature Genetics, suggests ...

Researchers map 'family trees' of acute myeloid leukemia

July 16, 2018
For the first time, a team of international researchers has mapped the family trees of cancer cells in acute myeloid leukaemia (AML) to understand how this blood cancer responds to a new drug, enasidenib. The work also explains ...

Looking at the urine and blood may be best in diagnosing myeloma

July 13, 2018
When it comes to diagnosing a condition in which the plasma cells that normally make antibodies to protect us instead become cancerous, it may be better to look at the urine as well as the serum of our blood for answers, ...

Massive genome havoc in breast cancer is revealed

July 12, 2018
In cancer cells, genetic errors wreak havoc. Misspelled genes, as well as structural variations—larger-scale rearrangements of DNA that can encompass large chunks of chromosomes—disturb carefully balanced mechanisms that ...

Study shows biomarker panel boosts lung cancer risk assessment for smokers

July 12, 2018
A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history, capturing risk for people who have ever smoked, not only for heavy smokers, an international ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.